Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TMO ramps up acquisitions and product launches to drive growth, but heavy debt and currency headwinds raise questions for long-term holders.
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Thermo Fisher Scientific's pharmaceutical services business has won a number of contracts to help its customers move production from Europe or Asia to the U.S., the medical equipment maker's CEO, Marc Casper, said on Tuesday.
Danaher (NYSE: DHR) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher launches a global PPD CorEvitas Alzheimer's registry, enrolling its first patient to generate real-world safety and effectiveness data.
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
Thermo Fisher expands its Bioprocess Design Centers across Asia, boosting biomanufacturing speed, efficiency and regional innovation.
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.
Several key stocks are making notable buyback announcements. Below, we examine the latest moves by Trade Desk, Thermo Fisher, and Tapestry—and what they reveal about each company's capital return strategy.